Trial Profile
Efficacy and Safety of TULY in Prevention and Treatment of Malignancy-associated Hyperuricemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rasburicase (Primary)
- Indications Hyperuricaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Virchow Group
- 19 May 2015 New trial record